McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the ...

PepsiCo’s selloff presents the highest dividend yield in history. Find out why PEP stock might mirror the Dotcom bust ...

Ocean demand being pulled forward. The main debate regarding the container ship market is whether several factors will converge to tank rates later this year. Most industry profes ...

Q1 2025 Earnings Call Transcript February 10, 2025 Rockwell Automation, Inc. beats earnings expectations. Reported EPS is ...

Can GLP-1 Meds Harm Your Eyes? By Ernie Mundell HealthDay Reporter MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss ...

Are you a print subscriber? Activate your account. By Tim Nudd - 14 min 58 sec ago 2 hours 35 min ago By Parker Herren - 2 hours 48 min ago By Brian Bonilla - 2 hours 48 min ago By Jean-Paul ...

Now, diabetes specialists and cardiologists are among the specialists flocking to GLP-1 drugs to manage blood sugar and weight. In many ways, it's easier for physicians to access these drugs.

MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether the medications caused the eye ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney ...

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...

There is growing competition in the diaper market with Chinese brands entering the US, creating pricing pressure.s. Barclays ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.